DJIA 18,059.72 -20.42 -0.11%
NASDAQ 5,071.89 -20.20 -0.40%
S&P 500 2,113.38 -4.31 -0.20%
market minute promo

MannKind Corp (NASDAQ: MNKD)

4.61 -0.19 (-3.96%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

MNKD $4.60 -4.17%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.82
Previous Close $4.80
Daily Range $4.60 - $4.86
52-Week Range $4.45 - $11.48
Market Cap $1.9B
P/E Ratio -9.41
Dividend (Yield) $0.00 (0.0%)
Volume 4,088,919
Average Daily Volume 3,548,378
Current FY EPS -$0.34




Drug Makers

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website:

News & Commentary

MannKind Corporation: Past, Present, and Future

Let's learn about the history and future prospects of MannKind as it launches its first drug, Afrezza.

MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval

MannKind Corporation: A Good Risk/Reward Play For The Long Haul

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

Marketocracy Top 20 Manager, Nate Pile, Invested In MannKind And Afrezza

3 Questions to Ask Before You Buy a Biotech Stock

One Motley Fool analyst explains the key questions investors should answer before buying biotech stocks.

Pain-Free Blood Tests? Sign Me Up!

A small, Wisconsin-based company could be on the verge of developing a revolutionary new blood test that is virtually pain-free. Find out how personalized healthcare is transforming the medical field.

8 Analyst Stocks Under $10 With Massive Upside Calls

What's Afrezza's Ultimate Potential For MannKind?

Colorectal cancer biotech Xbiotech prices $76 million IPO at $19 midpoint

See More MNKD News...

MNKD's Top Competitors

MNKD $4.61 (-3.96%)
Current stock: MNKD
AMGN $162.53 (-3.20%)
Current stock: AMGN
GILD $102.57 (-1.08%)
Current stock: GILD
BIIB $389.86 (-2.95%)
Current stock: BIIB